Technion scientists have succeeded in producing an engineered lymph vessel network, opening path to novel lymphedema treatment

Technion scientists have managed to grow an engineered human lymphatic vessel network. Published in PNAS, the study was led by postdoctoral fellow Dr. Shira Landau and conducted in the laboratory of Professor Shulamit Levenberg of the Technion Faculty of Biomedical Engineering. The significance of the researchers’ findings lies in a better understanding of lymphatic vessel generation, which could have implications for treatment of lymphedema and the generation of more lifelike tissue flaps.

The lymphatic vessels are built similar to veins. They collect the fluid between the cells in all body tissues. This lymphatic fluid is collected by lymph capillaries, then transported via progressively larger lymphatic vessels through lymph nodes, before emptying ultimately into major veins. The lymphatic system also plays an important role in the body’s immune response. Damage to the lymphatic vessels results in localised swelling, a condition called lymphedema. Lymphedema currently has no cure. Common treatments that provide partial improvement include compression of the affected limb and massage. In severe cases, bypass surgery is prescribed.

In the lab, Dr. Shira Landau and her coresearchers grew human lymphatic vessels, together with blood vessels and supporting cells, creating engineered tissue with a functioning vessel network. This was done from inner-lining cells of lymphatic vessels, together with blood vessels respectively, together with support cells, all seeded on sheets of collagen – the main structural protein of the body’s connective tissue. That is, their engineered tissue mimics as closely as possible the body’s natural structures. From this seemingly simple starting point, the group had within a few days a network of vessels that displayed both the arrangement and the functionality expected of them in the body. The engineered tissue was further implanted into a mouse, and successfully integrated with the mouse’s lymph and blood vessels.

This success by the Technion scientists has multiple implications. First, the platform they grew would facilitate the study of lymphatic vessels, their formation, and the factors that affect them. Second, lymphedema, which currently lacks effective treatment, could be in the future treated by implanting a functional network of smaller and larger lymph vessels that would merge with the host’s system, all grown from the patient’s own cells, eliminating fear of rejection. Third, engineered tissue flaps, that is units containing multiple tissues necessary for transplantation, such as muscle, blood vessels, and connective tissue, could be made more lifelike, containing lymph vessels as well. This would improve the implant’s integration and speed up healing.

For more than a century, the Technion – Israel Institute of Technology has pioneered in science and technology education and delivered world-changing impact. Proudly a global university, the Technion has long leveraged boundary-crossing collaborations to advance breakthrough research and technologies. Now with a presence in three countries, the Technion will prepare the next generation of global innovators. Technion people, ideas and inventions make immeasurable contributions to the world, innovating in fields from cancer research and sustainable energy to quantum computing and computer science to do good around the world.

The American Technion Society supports visionary education and world-changing impact through the Technion – Israel Institute of Technology. Based in New York City, we represent thousands of US donors, alumni and stakeholders who invest in the Technion’s growth and innovation to advance critical research and technologies that serve the State of Israel and the global good. Since 1940, our nationwide supporter network has funded new Technion scholarships, research, labs, and facilities that have helped deliver world-changing contributions and extend Technion education to campuses in three countries.